GILD Gilead Sciences, Inc.
Trend channel, buy level and 3-month target. Information only, not financial advice.
Above the channel · 9-month channel rising
Closed above resistance (US$159.54). The fitted trend may no longer apply.
- 9-month channel read from
- US$148.09 – US$159.54 · rising, +8% a year
- 12-month channel
- US$145.62 – US$155.65 · rising, +21% a year
- Price in channel
- 200% (0% = floor, 100% = ceiling)
- Ceiling overhead
- none — above both ceilings
- Turns bearish below
- US$148.09
- Published levels
- Buy and target are not from this channel — see below.
Price history, with the path projected 3 months forward
Updated 3:10 AM ET (8 h ago)
- Daily close
- Upper trend line (9 months)
- Lower trend line (9 months)
- The same lines over the last 12 months
- Dashed after today: projected 3 months
- Our buy
- Our target
Our target
No published call: price has closed 7.3% clear above the channel, so the fitted lines no longer describe where it is Levels below are for reference only.
Buy at or below
US$148.13
level as at 1 Nov 2026
Our target
US$166.12
by 2 Nov 2026
Projected move
12.2%
gross, before costs
Price is at or past our target.
7 settled calls · 3 reached target (42.9%) · average best move 5.5%. See the full record.
- Upper line touches
- 4
- Lower line touches
- 3
- Fit confidence
- 76%
- Fitted
- 1 Nov 2026
Company information
About Gilead Sciences, Inc.
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Daniel O'Day
- Employees
- 17,000
- Country
- US
Scorecard
Our own scores from the fundamentals below (not Morningstar ratings).
- Valuation
- —
- Profitability
- —
- Financial health
- —
- Cash generation
- —
Key statistics
- Market cap
- US$179.47B
- Enterprise value
- —
- Beta
- 0.35
- Avg volume
- 7.07M
- Revenue per share
- —
- Dividend yield
- —
- 52-week range
- 112.41-157.29
- Exchange
- NASDAQ
Key ratios
- P/E (TTM)
- —
- PEG
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Current ratio
- —
- Quick ratio
- —
- Debt / equity
- —
- Interest cover
- —
Income statement
Balance sheet
Cash flow
Trend lines are fitted to past swing highs and lows and may not continue. Information only, not financial advice.